Twist Bioscience Corp [TWST] stock prices are down -1.81% to $40.25 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The TWST shares have gain 4.93% over the last week, with a monthly amount glided 15.76%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 22, February 2024, Twist Bioscience to Present at Upcoming Investor Conferences. In a post published today on Yahoo Finance, Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that its executives will participate in fireside chats at the following upcoming investor conferences:.
From an analyst’s perspective:
Twist Bioscience Corp [NASDAQ: TWST] stock has seen the most recent analyst activity on January 17, 2024, when Goldman upgraded its rating to a Buy and also boosted its price target to $45 from $25. Previously, Berenberg started tracking the stock with Buy rating on September 27, 2023, and set its price target to $27. On January 05, 2023, Scotiabank initiated with a Sector Outperform rating and assigned a price target of $33 on the stock. Evercore ISI upgraded its rating to a Outperform and increased its price target to $36 on January 03, 2023. In a note dated June 29, 2021, William Blair initiated an Outperform rating.
The stock price of Twist Bioscience Corp [TWST] has been fluctuating between $11.46 and $43.21 over the past year. Currently, Wall Street analysts expect the stock to reach $34 within the next 12 months. Twist Bioscience Corp [NASDAQ: TWST] shares were valued at $40.25 at the most recent close of the market. An investor can expect a potential drop of -15.53% based on the average TWST price forecast.
Analyzing the TWST fundamentals
The Twist Bioscience Corp [NASDAQ:TWST] reported sales of 262.36M for trailing twelve months, representing a surge of 31.81%. Gross Profit Margin for this corporation currently stands at 0.36% with Operating Profit Margin at -0.84%, Pretax Profit Margin comes in at -0.78%, and Net Profit Margin reading is -0.78%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.32 and Total Capital is -0.33. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.16.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 39.41 points at the first support level, and at 38.56 for the second support level. However, for the 1st resistance point, the stock is sitting at 41.34, and for the 2nd resistance point, it is at 42.42.
Twist Bioscience Corp [TWST] reported earnings per share of -$0.75 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.78/share, meaning a difference of $0.03 and a surprise factor of 3.80%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.81 per share as compared to estimates of -$0.92 per share, a difference of $0.11 representing a surprise of 12.00%.
Ratios To Look Out For
It’s worth pointing out that Twist Bioscience Corp [NASDAQ:TWST]’s Current Ratio is 5.98. Further, the Quick Ratio stands at 5.51, while the Cash Ratio is 4.08. Considering the valuation of this stock, the price to sales ratio is 8.87, the price to book ratio is 3.94.
Transactions by insiders
Recent insider trading involved CHESS ROBERT, Director, that happened on Feb 08 when 4110.0 shares were sold., Cho Dennis completed a deal on May 10 to buy 10000.0 shares.
